• Gabriele Mandarelli, Florenzo Iannone, Stefano Ferracuti, Ignazio Grattagliano, Marcello Benevento, Biagio Solarino, Davide Ferorelli, and Roberto Catanesi.
• "Aldo Moro" University of Bari, Bari, Italy.
• Eur. J. Clin. Invest. 2022 Sep 1; 52 (9): e13805e13805.

BackgroundThe need for highly effective therapies in rheumatologic diseases has led to the widespread and growing use of a heterogeneous class of molecules called biological agents. The increasing experience with biological agents has raised concerns about safety and efficacy issues that need to be discussed in the informed consent acquisition process.MethodsThe authors performed a review of the literature on biological agents focusing on their most important characteristics concerning the informed consent procedures.ResultsNo studies specifically addressed the issue of informed consent in patients receiving biological agents. Several studies reported data about off-label use of biological agents usually with no obvious attention to informed consent shortcomings.ConclusionThe reported association between biological agents and serious infections or malignancies, including reactivation of latent tuberculosis, needs specific disclosure in informed consent acquisition, together with information about the possible efficacy in clinical contexts often characterized by resistance to previous treatments. Ethical and clinical issues bound to the need for experimenting with new agents with potentially serious adverse effects deserve specific attention. Studies aimed at evaluating mental capacity to consent in subjects receiving biological agents are required.© 2022 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

8 keywords...

hide…